Search

In the last few years, gamma hydroxybutyric acid (GHB) has been used increasingly as a party drug; this has led to a marked increase in the number of requests for professional help with the treatment of GHB addiction. Pharmaceutical GHB (sodium oxybate, the sodium-salt of GHB), registered for cataplexia in narcolepsy patients, is used off-label to treat the withdrawal symptoms associated with GHB addiction. Pharmaceutical GHB has a high sodium load. In this report we present the cases of two patients who developed symptomatic hypernatremia following treatment with pharmaceutical GHB and who thereafter needed intensive care for the severe withdrawal symptoms that they experienced.

Two male infants, 6 and 2 months old, children of immigrant parents, were hospitalised because of somnolence and diarrhoea. Both had severe hypernatraemia. The first died during venous cannulation, the second had convulsions with multiple cerebral haemorrhages and severe neurologic damage. Both had received oral rehydration fluid, prescribed by their general practitioner and prepared by their parents. These had dissolved the contents of the package in far too little water, which resulted in solutions that were seven times and twice, respectively, as strong as they should have been. Careful instruction regarding the use and preparation of oral rehydration fluid is of utmost importance, notably with patients with a different cultural or language background.